Key Takeaways
- 25%+ growth ambition, backed by capacity: Management targets >25% CAGR revenue growth for the next 2-3 years, with core MCC utilization at ~90% and a clear path to expand capacity from 21,000 to 25,000 MTPA through low-cost debottlenecking.
- API segment pivots from volume to value: API revenue halved to INR29 crores as low-margin business was deliberately shed, but the segment swung from EBITDA-negative to ~20% EBITDA margin, with a target of 25%+ as CEP certifications unlock regulated markets.
- CCS plant is the next growth leg, but 18 months out: Environmental clearance is in hand for the Dahej-2 facility, with commissioning set for October 2026 and a peak revenue potential of INR300-360 crores, though first-year utilization is expected at only ~35%.
- Margins are structurally improving, not just cyclical: Q4 gross margin hit ~60% on product mix and O&M contribution; management sees current EBITDA margins as sustainable and expects them to go beyond 25% as higher-margin API and O&M segments scale.
- What to watch next quarter: Progress on the 5 additional CEP filings planned for CY2025, the pace of O&M segment scaling toward the INR75 crore FY26 target, and any quantification of the Middle East business opportunity management is pursuing this year.
Growth Engine: MCC Core & Capacity
- Utilization is tight, expansion is incremental: Blended MCC utilization sits at ~90%, and management plans to add 4,000 MTPA through debottlenecking (adding dryers, blenders, reactors) with only small capex, rather than a new greenfield line.
- New plant ramping on schedule: The 7,000 MTPA facility added recently is already at 68% utilization and expected to approach full capacity during FY26, providing near-term volume headroom.
- Market share gains come from two fronts: Growth is split between participating in customers' new formulation development (winning the excipient specification early) and displacing competitors on price for existing grades, though management declined to quantify the split across its 60 product grades.
- Pricing power is customer-specific, not formulaic: The company does not track SKU-level price increases systematically; realizations improve through cost optimization and favorable sales mix rather than automatic annual hikes, with raw material costs passed through on a contract-by-contract basis.
- US tariff exposure is being pushed to customers: Management is not absorbing the 10% US tariff; customers are currently taking the requirements, and if imports continue, the tariff will be added to customer pricing rather than hitting Sigachi's margins.
Amit Raj Sinha: "the global MCC market is growing at a 5-year CAGR of 6.5%, Sigachi has delivered a 5-year CAGR of 26.47%, a testament of our differentiated capabilities and sharp execution."
API Turnaround: From Loss-Maker to Margin Driver
- The deliberate reset: API revenue dropped from INR57 crores in FY24 to INR29 crores in FY25 because management walked away from low-margin, high-volume business that had made the segment EBITDA-negative. The result: a swing to ~20% EBITDA margin, with a target of 25% or higher.
- Regulatory unlocks are the next catalyst: The company secured its first CEP certification (Metformin HCL), opening European regulated markets, and has filed 4 more CEPs with 5 additional filings planned during calendar year 2025. A dedicated API R&D facility is being built to accelerate documentation, which had previously been slowed by sharing resources with manufacturing.
- Molecule focus for regulated entry: Six molecules are prioritized for regulated market entry on an accelerated timeline: Pregabalin, Metformin, Minoxidil, Retinovir, Meclizine, and Sitagliptin. Initial sales will skew toward non-regulated and domestic markets, with the regulated share rising as approvals come through.
- Capacity expansion is already planned: Additional capex will add 150 KL of API capacity (taking the total to 250 KL), signaling confidence that the regulated-market pipeline will need the volume.
CCS: The Next Big Bet, With a Long Fuse
- The plant is fully permitted and funded: Environmental clearance for the Dahej-2 SEZ CCS facility is secured, technical know-how already exists in-house, and FDA approval is not seen as a challenge given Sigachi's existing excipient and facility approvals. Commissioning is set for October 2026.
- The revenue math is compelling but back-end loaded: On an INR90 crore capex, peak revenue potential is INR300-360 crores, implying 3-4x asset turnover at maturity. However, first-year utilization is expected at only ~35%, with full capacity consumption taking 2 years and optimal asset turnover another 2 years beyond that.
- Capex spend is modest near-term: Only INR40-50 crores of the total INR90 crore CCS capex will be spent in FY26, with funding coming from IPO proceeds and the remainder from either debt or further issuance, though management did not specify the split.
- The competitive wedge is price: When pressed on how Sigachi will win CCS customers from established suppliers, management acknowledged that "price is the point where we jump in," while also noting that CCS is technically complementary to MCC in drug formulations (MCC binds the tablet, CCS acts as the disintegrant), creating a natural cross-sell into the existing customer base.
Amit Raj Sinha: "MCC acts as a binder, whereas a CCS acts as a disintegrant. So MCC puts the tablet together, whereas the CCS breaks up the tablet inside the body. So they are technically complementary and both of them have to be there in the drug."
O&M Services: The Quiet Scalability Story
- A stable, referenceable revenue stream: The O&M service business has evolved beyond a one-off into a scalable segment, adding Adani Solar as a key client during the year and now contributing ~9% of total revenue.
- Doubling ambition for FY26: Management expects O&M revenue to reach approximately INR75 crores in FY26, roughly double the current run-rate, and noted it could exceed that figure if favorable contracts are awarded.
- Margin profile supports the blended target: While segment-level margins for O&M were not disclosed, the segment's contribution to the Q4 gross margin improvement to ~60% suggests it carries healthy profitability that supports the overall target of sustaining and exceeding 25% EBITDA margins.
Capital Allocation & Governance
- Preferential allotment forfeiture: INR25 crores was forfeited from allottees who failed to pay; no shares were issued against that amount, and the sum was accounted under Capital Reserve rather than flowing through the P&L. Management stated that disclosures were made in four tranches and filed with the ROC as public documents, though an analyst noted the absence of cash flow disclosures.
- Promoter pledging increased, with a stated rationale: Promoter pledges rose from 23% to 44%, with management explaining that the entire proceeds were invested in preferential equity shares of the company when the share price was lower, framing it as an alignment move rather than a liquidity event.
- No revenue mix roadmap for the INR1,000 crore target: When asked to break down how the INR1,000 crore revenue ambition splits among MCC, CCS, API, and O&M, management declined to provide exact ratios, stating only that O&M and API shares will increase and all segments are expected to grow at not less than 25% on average.
Amit Raj Sinha: "We keep exploring options, but we don't really get into it until we understand the complete 5 forces model... we don't really jump in because the moment we jump in, somebody else is ready to take my position in the pharma industry, where my kind of leadership is already cemented."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Revenue CAGR | >25% consolidated revenue growth | Next 2-3 years |
| EBITDA margin | Sustain current levels and go beyond 25% | Ongoing, no end date |
| MCC capacity | Expand from 21,000 to 25,000 MTPA via debottlenecking | Once optimum utilization is reached |
| CCS plant commissioning | Begin production at Dahej-2 SEZ facility | October 2026 |
| CCS utilization ramp | ~35% in Year 1; full capacity within 2 years; 3-4x asset turnover in another 2 years | FY27 through FY30 |
| CCS capex spend | INR40-50 crores | FY26 |
| O&M revenue | Double to ~INR75 crores | FY26 |
| API EBITDA margin | Target ~25%, possibly higher | Ongoing |
| API CEP filings | 5 additional filings | Calendar year 2025 |
| API capacity | Add 150 KL (total 250 KL) | Not specified |
| Segment growth floor | All segments (MCC, API, O&M, CCS) to grow at not less than 25% on average | Ongoing |
| Per-kg value growth | 4-5% annual improvement expected to continue | Ongoing |
Key Metrics
| Metric | Q4 FY25 |
|---|---|
| Total operating income | ₹128 cr, +23.15% YoY |
| EBITDA | ₹28.5 cr, +74.84% YoY; margin 22.31% |
| Net profit | ₹16.2 cr, +7.28% YoY; PAT margin 12.63% |
| MCC segment revenue | ₹121.32 cr, +55.08% YoY |
| O&M segment revenue | ₹10.76 cr, +17.9% YoY |
| FY25 full-year operating income | ₹500 cr, +25.42% over FY24 |
| FY25 full-year EBITDA | ₹112 cr, +46.21% YoY; margin 22.38% |
| FY25 full-year net profit | ₹70.5 cr, +23.25% YoY; PAT margin 14.09% |
| FY25 full-year MCC segment revenue | ₹409 cr, +35.75% from ₹302 cr in FY24 |
| FY25 full-year O&M segment revenue | ₹41 cr, +17.66% YoY |
| FY25 full-year API segment revenue | ₹29 cr |
| Revenue growth outlook | >25% CAGR over next 2–3 years |
| Sustainable EBITDA margin target | Beyond 25% |
| MCC current pricing | ₹214.3 per kg |
| MCC capacity utilization | 19,100 tons produced; capacity 21,000 MTPA, augmentable to 25,000 MTPA via debottlenecking |
| New 7,000 MTPA plant utilization | 68%, expected to scale near full capacity by FY26 |
| CCS plant capex | ₹90 cr; commissioning expected October 2026 |
| CCS asset turnover target | 3–4x over time |
| O&M segment FY26 revenue target | ~₹75 cr |
| API EBITDA margin | ~20% in FY25 |
| API plant capacity utilization | ~35–40% on a full-year basis |
| Top 5 customer concentration | 43.98% of revenue |
| Top 10 customer concentration | ~60% of revenue |
| Total customer base | ~350 in FY25, may exceed 500 overall |
| CEP certifications | 4 filed, 1 secured for Metformin HCL; 5 more planned this calendar year |
| Forfeited preferential allotment amount | ₹25 cr, accounted under capital reserve |